CNTA Valuation
Centessa Pharmaceuticals PLC
$
17.640
- Overview
- Forecast
- Valuation
- Earnings
CNTA Relative Valuation
CNTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CNTA is overvalued; if below, it's undervalued.
Historical Valuation
Centessa Pharmaceuticals PLC (CNTA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.50. The fair price of Centessa Pharmaceuticals PLC (CNTA) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：17.64
Fair
-11.56
PE
1Y
3Y
5Y
Trailing
Forward
-10.16
EV/EBITDA
Centessa Pharmaceuticals PLC. (CNTA) has a current EV/EBITDA of -10.16. The 5-year average EV/EBITDA is -3.96. The thresholds are as follows: Strongly Undervalued below -11.18, Undervalued between -11.18 and -7.57, Fairly Valued between -0.36 and -7.57, Overvalued between -0.36 and 3.25, and Strongly Overvalued above 3.25. The current Forward EV/EBITDA of -10.16 falls within the Undervalued range.
-10.26
EV/EBIT
Centessa Pharmaceuticals PLC. (CNTA) has a current EV/EBIT of -10.26. The 5-year average EV/EBIT is -3.68. The thresholds are as follows: Strongly Undervalued below -10.36, Undervalued between -10.36 and -7.02, Fairly Valued between -0.35 and -7.02, Overvalued between -0.35 and 2.99, and Strongly Overvalued above 2.99. The current Forward EV/EBIT of -10.26 falls within the Undervalued range.
0.00
PS
Centessa Pharmaceuticals PLC. (CNTA) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-13.87
P/OCF
Centessa Pharmaceuticals PLC. (CNTA) has a current P/OCF of -13.87. The 5-year average P/OCF is -8.06. The thresholds are as follows: Strongly Undervalued below -29.04, Undervalued between -29.04 and -18.55, Fairly Valued between 2.44 and -18.55, Overvalued between 2.44 and 12.93, and Strongly Overvalued above 12.93. The current Forward P/OCF of -13.87 falls within the Historic Trend Line -Fairly Valued range.
-13.49
P/FCF
Centessa Pharmaceuticals PLC. (CNTA) has a current P/FCF of -13.49. The 5-year average P/FCF is -4.31. The thresholds are as follows: Strongly Undervalued below -13.86, Undervalued between -13.86 and -9.08, Fairly Valued between 0.47 and -9.08, Overvalued between 0.47 and 5.24, and Strongly Overvalued above 5.24. The current Forward P/FCF of -13.49 falls within the Undervalued range.
Centessa Pharmaceuticals PLC (CNTA) has a current Price-to-Book (P/B) ratio of 5.92. Compared to its 3-year average P/B ratio of 3.21 , the current P/B ratio is approximately 84.30% higher. Relative to its 5-year average P/B ratio of 3.58, the current P/B ratio is about 65.03% higher. Centessa Pharmaceuticals PLC (CNTA) has a Forward Free Cash Flow (FCF) yield of approximately -7.30%. Compared to its 3-year average FCF yield of -26.00%, the current FCF yield is approximately -71.92% lower. Relative to its 5-year average FCF yield of -23.27% , the current FCF yield is about -68.62% lower.
5.92
P/B
Median3y
3.21
Median5y
3.58
-7.30
FCF Yield
Median3y
-26.00
Median5y
-23.27
Competitors Valuation Multiple
The average P/S ratio for CNTA's competitors is 4.12, providing a benchmark for relative valuation. Centessa Pharmaceuticals PLC Corp (CNTA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CNTA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CNTA in the past 1 year is driven by Unknown.
People Also Watch
ASTH
Astrana Health Inc
29.540
USD
-0.30%
CEPU
Central Puerto SA
11.910
USD
-3.41%
FWONA
Formula One Group
88.395
USD
-1.16%
APLD
Applied Digital Corp
14.550
USD
-1.69%
LION
Lionsgate Studios Corp
6.550
USD
+0.61%
HSAI
Hesai Group
23.320
USD
+0.09%
ZIM
ZIM Integrated Shipping Services Ltd
16.960
USD
-2.58%
WLY
John Wiley & Sons Inc
39.410
USD
-2.28%
OMCL
Omnicell Inc
31.470
USD
+0.41%
VITL
Vital Farms Inc
47.750
USD
+0.02%
FAQ
Is Centessa Pharmaceuticals PLC (CNTA) currently overvalued or undervalued?
Centessa Pharmaceuticals PLC (CNTA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.50. The fair price of Centessa Pharmaceuticals PLC (CNTA) is between to according to relative valuation methord.
What is Centessa Pharmaceuticals PLC (CNTA) fair value?
How does CNTA's valuation metrics compare to the industry average?
What is the current P/B ratio for Centessa Pharmaceuticals PLC (CNTA) as of Aug 14 2025?
What is the current FCF Yield for Centessa Pharmaceuticals PLC (CNTA) as of Aug 14 2025?
What is the current Forward P/E ratio for Centessa Pharmaceuticals PLC (CNTA) as of Aug 14 2025?